🔬 Current Disease Focus:
Task Progress: 0%
👥 Active Problem Solvers
0
🌍 Experts collaborating globally
⚡ Current Task Assignment
🧬 Genetic Analysis
🔄 Matching experts to specific tasks
📊 Resource Allocation by Research Phase:
📚 Data Analysis
🧪 Experimental Design
🔬 Clinical Trials
💊 Treatment Development
The purpose of this study is to assess the safety, pharmacokinetic, pharmac...
Status
Unknown
Location
Henan Provincial Oncology Hospital
Start Date
2022-06-14
Trial ID
NCT05186012
APG-1252 is a highly potent Bcl-2 family protein inhibitor, a promising dru...
Status
Terminated
Location
The First Affiliated Hospital of Sun Yat-Sen University
Start Date
2022-01-06
Trial ID
NCT04893759
Treatments Being Tested
This is a multi-center, open-label, phase Ib/II study of combination therap...
Status
Terminated
Location
BRCR Medical Center
Start Date
2020-08-20
Trial ID
NCT04210037
Treatments Being Tested
APG-1252 is a highly potent Bcl-2 family protein inhibitor, a promising dru...
Status
Completed
Location
START Midwest
Start Date
2017-02-12
Trial ID
NCT03080311
Treatments Being Tested
The study is a designed to evaluate safety and activity of APG-1252 when ad...
Status
Withdrawn
Location
Banner MD Anderson Cancer Center
Start Date
2020-12-15
Trial ID
NCT04354727
Treatments Being Tested
APG-1252 is a highly potent Bcl-2 family protein inhibitor, a promising dru...
Status
Terminated
Location
Guangdong General Hospital
Start Date
2017-12-01
Trial ID
NCT03387332
Treatments Being Tested
There are unmet medical needs in patients who resist to EGFR TKIs, especial...
Status
Active Not Recruiting
Location
Sun-Yat Sen University Cancer Center
Start Date
2019-07-04
Trial ID
NCT04001777
Treatments Being Tested
This phase I trial tests the safety, side effects, and best dose of combina...
Status
Active Not Recruiting
Location
Emory University Hospital/Winship Cancer Institute
Start Date
2023-09-14
Trial ID
NCT05691504
This is a phase Ib/II study that aims to investigate the safety, tolerabili...
Status
Recruiting
Location
UT MD Anderson
Start Date
2026-05-22
Trial ID
NCT07508982
Treatments Being Tested